Zum Inhalt springen Zur Suche springen

Juergens

  • Kutzsche J, Guzman GA, Willuweit A, Kletke O, Wollert E, Gering I, Jürgens D, Breitkreutz J, Stark H, Beck-Sickinge AG, Klöcker N, Hidalgo P, Willbold D. 
    An orally available N-type calcium channel inhibitor for the treatment of neuropathic pain.  
    Br J Pharmacol. , (2023) 
    https://pubmed.ncbi.nlm.nih.gov/38157867/  
  • Kutzsche J, Schemmert S, Bujnicki T, Zafiu C, Halbgebauer S, Kraemer-Schulien V, Pils M, Blömeke L, Post J, Kulawik A, Jürgens D, Rossberg WM, Hümpel M, Bannach O, Otto M, Araujo JA, Willuweit A, Willbold D. 
    Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease  
    Heliyon 29;9(8):e18443, (2023) 
    https://pubmed.ncbi.nlm.nih.gov/37609390/  
  • Kutzsche J, Jürgens D, Willuweit A, Adermann K, Fuchs C, Simons S, Windisch M, Hümpel M, Rossberg W, Wolzt M, Willbold D. 
    Safety and Pharmacokinetics of the Orally Available Antiprionic Compound PRI-002: A Single and Multiple Ascending Dose Phase I Study 
    Alzheimers Dement (N Y) , 20;6(1):e12001 (2020) 
    https://pubmed.ncbi.nlm.nih.gov/32211506/  
  • Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen KJ, Demuth HU, Shah NJ, Kutzsche J, Willuweit A, Willbold D 
    Aβ oligomer eliminating compounds interfere successfully with pEAβ (3–42) induced motor neurodegenerative phenotype in transgenic mice 
    Neuropeptides 67, 27-35 (2018) 
    https://doi.org/10.1016/j.npep.2017.11.011  
    https://www.sciencedirect.com/science/article/pii/S0143417917301531  
  • Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D. 
    Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease. 
    Molecules 22(10), (2017) 
    http://10.3390/molecules22101693  
    https://www.ncbi.nlm.nih.gov/pubmed/28994710  
  • van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D. 
    The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. 
    Sci Rep. 7, 16275 (2017) 
    https://doi.org/10.1038/s41598-017-16565-1  
    https://www.nature.com/articles/s41598-017-16565-1  
  • Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen K-J, Demuth H-U, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D 
    QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. 
    Sci Rep 5, 13222 (2015) 
    http://dx.doi.org/10.1038/srep13222